Immunovant, Inc.

Immunovant, Inc.

IMVTNYSE / NASDAQHealthcareSmall cap

$31.77-$0.75 (-2.3%)

Last close · Data as of Nov 20, 2026

Market cap
$6.7B
P/E
-13.3x
EV / EBITDA
-10.9x
Revenue
$0.00
ROCE
-62.5%

+39.4% over the last year

Immunovant, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+11.1%
3M
-28.4%
6M
-10.7%
1Y
+39.4%
5Y
+286.5%

52-week range

Day change -$0.75 (-2.3%) from $33 to $32 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IMVT, bought on each weekday since 2021.

News & filings

What Immunovant filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 506 million US dollars in fiscal 2026.

Strengths (1)

  • Current assets are 9.09 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2026

Rule-based from financial data. Not advice.

About the company

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Sector
Healthcare
Shares outstanding
203.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.7B
P/E
-13.3x
P/B
7.9x
EV / EBITDA
-10.9x
52-week high
$44.96
52-week low
$22.02

Profitability

ROE
-59.3%
ROCE
-62.5%
ROA
-52.8%

Growth

Revenue
$0.00
Net profit growth, 1Y
22.2%
Free cash flow
-$407.3M

Solvency

Current ratio
9.09
Debt / Equity
0.00
Debt / Assets
0.00
CFO / Net profit
0.81
Cash / Market cap
13.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Immunovant, Inc. revenue and net profit by fiscal year
Immunovant, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2023$0.00-$211.0M
FY2024$0.00-$259.3M
FY2025$0.00-$413.8M
FY2026$0.00-$505.6M

Cash flows

FY2026: -$407.3M from operations, -$407.3M free after investment (dashed).

Immunovant, Inc. operating and free cash flow by fiscal year
Immunovant, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2023-$188.2M-$188.4M
FY2024-$214.2M-$214.6M
FY2025-$375.9M-$376.6M
FY2026-$407.3M-$407.3M

Growth

Latest fiscal year 2026: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$532.5M
Net profit
-$505.6M
Cash from operations
-$407.3M
Free cash flow
-$407.3M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2026$0.00-$532.5M-$505.6M-$407.3M-59.3%—+22.2%

Monthly returns

Month-by-month returns of IMVT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2026.

LineFY2026
Assets$957.0M
Liabilities$104.4M
Non-current liabilities$0.00
Equity$852.6M
Paid-in capital$2.6B
Retained earnings-$1.7B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IMVT highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Immunovant, Inc., Vaxcyte, Inc., Apogee Therapeutics, Inc., Spyre Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Immunovant, Inc.IMVTthis company$6.7B-13.3x7.9x-59.3%-10.9x
HealthEquity, Inc.HQY$7.2B33.4x3.4x10.2%16.1x
Oscar Health, Inc.OSCR$7.1B-16.1x7.3x-45.3%—
Vaxcyte, Inc.PCVX$7.0B-9.2x2.6x-28.5%-7.8x
Apogee Therapeutics, Inc.APGE$6.9B-26.8x7.6x-28.3%-23.7x
Spyre Therapeutics, Inc.SYRE$6.8B—9.5x-21.7%—
Arcellx, Inc.ACLX$6.7B-29.4x16.7x-56.9%-30.2x
Lantheus Holdings, Inc.LNTH$6.7B28.7x6.1x21.4%17.2x
Hims & Hers Health, Inc.HIMS$6.5B50.5x12.0x23.7%46.1x
Peer median—-9.2x7.4x-25.0%4.2x

Year-to-date ROI

IMVT since 1 January, against earlier years.

Historical volatility

IMVT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2026
Operating expensesOperating Expense$532.9M
Research and developmentResearch And Development$456.7M
Total expensesTotal Expenses$532.9M
Operating incomeOperating Income-$532.9M
Pretax incomePretax Income-$505.4M

Learn while you research

Academy chapters picked for Immunovant, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →